Tonse, Raees
Townsend, Alexandra
Rubens, Muni
Siomin, Vitaly
McDermott, Michael W.
Tom, Martin C.
Hall, Matthew D.
Odia, Yazmin
Ahluwalia, Manmeet S.
Mehta, Minesh P.
Kotecha, Rupesh
Article History
Received: 15 June 2021
Accepted: 18 October 2021
First Online: 12 November 2021
Competing interests
: R. Tonse: None. A. Townsend: None. M. Rubens: None. V. Siomin: None. M. W. McDermott: Consulting for Deinde Medical and Stryker Corporation. M. Tom: Institutional research funding from Blue Earth Diagnostics Ltd. M. Hall: Honorarium from Accuray, Inc. Proton Collaborative Group Executive Committee Institutional Representative and Voting Member, Miami Cancer Institute (unpaid). Grant Funding: Live Like Bella Pediatric Cancer Research Initiative, Florida Department of Health Grant 8LA04. Y. Odia: No conflicts of interest; Trial Support (BMS, Novocure), DSMC (GammaTile, Actuate, Oncoceutics/Chimerix), Advisory Board (Novocure, Abbvie), and Consulting (Abbvie). M. S. Ahluwalia: Receipt of grants/research supports: Astrazeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure, Mimivax, Merck. Receipt of honoraria or consultation fees: Bayer, Novocure, Kiyatec, Insightec, GSK, Nuvation, Cellularity, Apollomics. Stock shareholder: Doctible, Mimivax, Cytodyn. M.P. Mehta: Consulting for Karyopharm, Sapience, Zap, Mevion. Board of Directors: Oncoceutics. R. Kotecha: Honoraria from Accuray Inc., Elekta AB, Viewray Inc., Novocure Inc., Elsevier Inc. Institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, Astrazeneca, Exelixis, Viewray Inc.